Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Double-blind Placebo-controlled Trial of Metformin for Cognitive Recovery and White Matter Growth in Paediatric Patients With a Brain Tumour

NCT05230758 is registered in ClinicalTrials.gov with Donald Mabbott as lead sponsor.

NCT NCT05230758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05230758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Double-blind Placebo-controlled Trial of Metformin for Cognitive Recovery and White Matter Growth in Paediatric Patients With a Brain Tumour
Lead sponsor
Donald Mabbott
Phase
Phase 3
Overall status
Recruiting
Start date
July 1, 2022
Completion date
November 30, 2027
Enrollment
140 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, medulloblastoma, childhood